{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:17:33Z","timestamp":1790799453500,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40262-021-01034-w","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T05:04:27Z","timestamp":1622264667000},"page":"1449-1462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients"],"prefix":"10.1007","volume":"60","author":[{"given":"B\u00e9n\u00e9dicte","family":"Franck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Autmizguine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Th\u00e9or\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ovetchkine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0695","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Woillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102:900\u201331.","journal-title":"Transplantation"},{"issue":"9","key":"1034_CR2","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","volume":"33","author":"RR Razonable","year":"2019","unstructured":"Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients: guidelines of the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33(9):e13512.","journal-title":"Clin Transplant."},{"issue":"23","key":"1034_CR3","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","volume":"113","author":"M Boeckh","year":"2009","unstructured":"Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711\u20139.","journal-title":"Blood"},{"key":"1034_CR4","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1128\/AAC.02953-14","volume":"58","author":"E Gim\u00e9nez","year":"2014","unstructured":"Gim\u00e9nez E, Solano C, Azanza JR, Amat P, Navarro D. Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. Antimicrob Agents Chemother. 2014;58:5602\u20135.","journal-title":"Antimicrob Agents Chemother."},{"key":"1034_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/tid.12317","volume":"16","author":"JP Gagermeier","year":"2014","unstructured":"Gagermeier JP, Rusinak JD, Lurain NS, Alex CG, Dilling DF, Wigfield CH, et al. Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients. Transpl Infect Dis. 2014;16:941\u201350.","journal-title":"Transpl Infect Dis."},{"key":"1034_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01855-18","volume":"63","author":"BM Ritchie","year":"2019","unstructured":"Ritchie BM, Barreto JN, Barreto EF, Crow SA, Dierkhising RA, Jannetto PJ, et al. Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety. Antimicrob Agents Chemother. 2019;63:10.","journal-title":"Antimicrob Agents Chemother."},{"key":"1034_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","volume":"79","author":"H Wiltshire","year":"2005","unstructured":"Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477\u201383.","journal-title":"Transplantation"},{"key":"1034_CR8","unstructured":"Genentech, Inc. Valcyte monography. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021304s008,022257s003lbl.pdf. Accessed 5 May 2021."},{"key":"1034_CR9","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1128\/AAC.02130-15","volume":"60","author":"A Padull\u00e9s","year":"2016","unstructured":"Padull\u00e9s A, Colom H, Bestard O, Melilli E, Sab\u00e9 N, Rigo R, et al. Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients. Antimicrob Agents Chemother. 2016;60:1992\u20132002.","journal-title":"Antimicrob Agents Chemother."},{"key":"1034_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/petr.12179","volume":"18","author":"A \u00c5sberg","year":"2014","unstructured":"\u00c5sberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant. 2014;18:103\u201311.","journal-title":"Pediatr Transplant."},{"key":"1034_CR11","doi-asserted-by":"publisher","first-page":"e01192","DOI":"10.1128\/AAC.01192-19","volume":"63","author":"A Facchin","year":"2019","unstructured":"Facchin A, Elie V, Benyoub N, Magreault S, Maisin A, Storme T, et al. Population pharmacokinetics of ganciclovir after valganciclovir treatment in children with renal transplant. Antimicrob Agents Chemother. 2019;63:e01192-e1219.","journal-title":"Antimicrob Agents Chemother."},{"key":"1034_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/petr.12030","volume":"17","author":"D Villeneuve","year":"2013","unstructured":"Villeneuve D, Brothers A, Harvey E, Kemna M, Law Y, Nemeth T, et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant. 2013;17:80\u20135.","journal-title":"Pediatr Transplant."},{"key":"1034_CR13","first-page":"1098","volume":"317","author":"R Mosteller","year":"1987","unstructured":"Mosteller R. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.","journal-title":"N Engl J Med."},{"key":"1034_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","volume":"34","author":"GJ Schwartz","year":"1987","unstructured":"Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am. 1987;34:571\u201390.","journal-title":"Pediatr Clin N Am."},{"key":"1034_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/INF.0000000000001595","volume":"36","author":"O Peled","year":"2017","unstructured":"Peled O, Berkovitch M, Rom E, Bilavsky E, Bernfeld Y, Dorfman L, et al. Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study. Pediatr Infect Dis J. 2017;36:745\u201350.","journal-title":"Pediatr Infect Dis J."},{"key":"1034_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/jpids\/piw008","volume":"5","author":"C Stockmann","year":"2016","unstructured":"Stockmann C, Sherwin CMT, Knackstedt ED, Hersh AL, Pavia AT, Spigarelli MG. Therapeutic drug monitoring of ganciclovir treatment for cytomegalovirus infections among immunocompromised children. J Pediatric Infect Dis Soc. 2016;5:231\u20132.","journal-title":"J Pediatric Infect Dis Soc."},{"key":"1034_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1517\/17425255.2015.988139","volume":"11","author":"C Stockmann","year":"2015","unstructured":"Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol. 2015;11:205\u201319.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1034_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0b013e3182509e3a","volume":"34","author":"W Zhao","year":"2012","unstructured":"Zhao W, Fakhoury M, Fila M, Baudouin V, Desch\u00eanes G, Jacqz-Aigrain E. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. Ther Drug Monit. 2012;34:326\u201330.","journal-title":"Ther Drug Monit."},{"key":"1034_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchromb.2008.01.046","volume":"864","author":"M Kasiari","year":"2008","unstructured":"Kasiari M, Gikas E, Georgakakou S, Kazanis M, Panderi I. Selective and rapid liquid chromatography\/negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;864:78\u201386.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"1034_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003088-200140050-00004","volume":"40","author":"J Debord","year":"2001","unstructured":"Debord J, Risco E, Harel M, Le Meur Y, B\u00fcchler M, Lach\u00e2tre G, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet. 2001;40:375\u201382.","journal-title":"Clin Pharmacokinet."},{"key":"1034_CR21","unstructured":"Keizer R. Vpc: create visual predictive checks. 2020. https:\/\/CRAN.R-project.org\/package=vpc. Accessed 15 Jul 2020."},{"key":"1034_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00478.x","volume":"12","author":"MD Pescovitz","year":"2010","unstructured":"Pescovitz MD, Ettenger RB, Strife CF, Sherbotie JR, Thomas SE, McDiarmid S, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis. 2010;12:195\u2013203.","journal-title":"Transpl Infect Dis."},{"key":"1034_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/j.1600-6143.2008.02528.x","volume":"9","author":"W Vaudry","year":"2009","unstructured":"Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636\u201343.","journal-title":"Am J Transplant."},{"key":"1034_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/00003088-200948050-00004","volume":"48","author":"W Zhao","year":"2009","unstructured":"Zhao W, Baudouin V, Zhang D, Desch\u00eanes G, Guellec CL, Jacqz-Aigrain E. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet. 2009;48:321\u20138.","journal-title":"Clin Pharmacokinet."},{"key":"1034_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/bcp.12343","volume":"78","author":"HE Vezina","year":"2014","unstructured":"Vezina HE, Brundage RC, Balfour HH. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients: population pharmacokinetics of valganciclovir prophylaxis after transplantation. Br J Clin Pharmacol. 2014;78:343\u201352.","journal-title":"Br J Clin Pharmacol."},{"key":"1034_CR26","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1097\/INF.0000000000001317","volume":"35","author":"D Bradley","year":"2016","unstructured":"Bradley D, Moreira S, Subramoney V, Chin C, Ives J, Wang K. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients 4 months of age and younger. Pediatr Infect Dis J. 2016;35:1324\u20138.","journal-title":"Pediatr Infect Dis J."},{"key":"1034_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cpt1979263294","volume":"26","author":"L Sheiner","year":"1979","unstructured":"Sheiner L, Beal S, Rosenberg B, Marathe V. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294\u2013305.","journal-title":"Clin Pharmacol Ther"},{"key":"1034_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/FTD.0000000000000007","volume":"36","author":"A Padull\u00e9s Cald\u00e9s","year":"2014","unstructured":"Padull\u00e9s Cald\u00e9s A, Colom H, Caldes A, Cerezo G, Torras J, Griny\u00f3 JM, et al. Optimal sparse sampling for estimating ganciclovir\/valganciclovir AUC in solid organ transplant patients using NONMEN. Ther Drug Monit. 2014;36:371\u20137.","journal-title":"Ther Drug Monit."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01034-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01034-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01034-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T03:28:34Z","timestamp":1636687714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01034-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01034-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]},"assertion":[{"value":"28 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by the internal funds from the CHU Sainte-Justine Research Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julie Autmizguine received salary support from the FRQS (Fonds de Recherche Sant\u00e9 Qu\u00e9bec), and consults for Astellas Pharma Inc. B\u00e9n\u00e9dicte Franck, Anders \u00c5sberg, Yves Th\u00e9or\u00eat, Pierre Marquet, Philippe Ovetchkine, and Jean-Baptiste Woillard have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The Institutional Review Board of the CHU Sainte-Justine approved the protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Code is available upon request (Rfile).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"BF and JBW conceived, designed, and performed the analysis. BF, JA, and JBW wrote the paper. JA, A\u00c5, and PO conceived and collected the data. YT performed the analyses of samples. JA, A\u00c5, PM, and PO contributed to the data analysis and to manuscript writing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}